MedPath

HOAG MEMORIAL HOSPITAL PRESBYTERIAN

🇺🇸United States
Ownership
-
Established
1952-01-01
Employees
-
Market Cap
-
Website
http://www.hoag.org/Pages/Home.aspx

Clinical Trials

30

Active:3
Completed:15

Trial Phases

3 Phases

Phase 1:1
Phase 2:17
Not Applicable:5

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (23 trials with phase data)• Click on a phase to view related trials

Phase 2
17 (73.9%)
Not Applicable
5 (21.7%)
Phase 1
1 (4.3%)

A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer

Phase 1
Recruiting
Conditions
Prostate Adenocarcinoma
Interventions
First Posted Date
2024-12-16
Last Posted Date
2024-12-16
Lead Sponsor
Hoag Memorial Hospital Presbyterian
Target Recruit Count
8
Registration Number
NCT06736054
Locations
🇺🇸

Hoag Memorial Hospital Presbyterian, Irvine, California, United States

Study of Dotatate Imaging in Breast Cancer

Phase 2
Active, not recruiting
Conditions
Breast Cancer Stage IV
First Posted Date
2023-05-30
Last Posted Date
2024-02-12
Lead Sponsor
Hoag Memorial Hospital Presbyterian
Target Recruit Count
30
Registration Number
NCT05880394
Locations
🇺🇸

Hoag Memorial Hospital Presbyterian, Irvine, California, United States

Pancreatic Cancer Early Detection Registry

Completed
Conditions
Pancreatic Cancer
First Posted Date
2022-08-29
Last Posted Date
2024-10-11
Lead Sponsor
Hoag Memorial Hospital Presbyterian
Target Recruit Count
326
Registration Number
NCT05519930
Locations
🇺🇸

Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States

18F-fluoroestradiol (FES) PET/CT for Breast Cancer

Phase 2
Active, not recruiting
Conditions
Breast Cancer
First Posted Date
2021-05-12
Last Posted Date
2023-09-28
Lead Sponsor
Hoag Memorial Hospital Presbyterian
Target Recruit Count
124
Registration Number
NCT04883814
Locations
🇺🇸

Hoag Memorial Hospital Presbyterian, Irvine, California, United States

A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma

Phase 2
Recruiting
Conditions
Multiple Myeloma
Interventions
Drug: 89Zr-daratumumab PET/CT
First Posted Date
2021-03-24
Last Posted Date
2023-06-27
Lead Sponsor
Hoag Memorial Hospital Presbyterian
Target Recruit Count
60
Registration Number
NCT04814615
Locations
🇺🇸

Hoag Memorial Hospital Presbyterian, Irvine, California, United States

🇺🇸

University of Miami, Miami, Florida, United States

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next

News

PanTher Therapeutics Initiates Phase 1b Trial of Novel Localized Chemotherapy Film for Pancreatic Cancer

PanTher Therapeutics has dosed the first patient in a Phase 1b clinical trial of PTM-101, an innovative thin film formulation of paclitaxel designed for direct tumor placement in pancreatic ductal adenocarcinoma.

Regeneration Biomedical Reports Promising Phase 1 Results for Direct Brain Injection of Stem Cells in Alzheimer's Disease

Regeneration Biomedical's Phase 1 trial of Wnt-activated autologous stem cells injected directly into the brain showed 80% of Alzheimer's patients improved cognitive scores and normalized biomarkers.

NUCLIDIUM's Copper-Based Radiotracer Shows Enhanced Imaging Performance in First Prostate Cancer Patient

NUCLIDIUM's 61Cu-NODAGA-PSMA I&T radiotracer successfully imaged the first patient in a phase 1 trial, showing more osseous lesions than FDA-approved 18F-piflufolastat at 1 hour post-injection.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.